HRP20120676T1 - Uporaba tiomiozina 1, samog ili u kombinaciji s ptx3 ili ganciklovirom, za liječenje citomegalovirusne infekcije - Google Patents

Uporaba tiomiozina 1, samog ili u kombinaciji s ptx3 ili ganciklovirom, za liječenje citomegalovirusne infekcije Download PDF

Info

Publication number
HRP20120676T1
HRP20120676T1 HRP20120676TT HRP20120676T HRP20120676T1 HR P20120676 T1 HRP20120676 T1 HR P20120676T1 HR P20120676T T HRP20120676T T HR P20120676TT HR P20120676 T HRP20120676 T HR P20120676T HR P20120676 T1 HRP20120676 T1 HR P20120676T1
Authority
HR
Croatia
Prior art keywords
thiomyosin
treatment
ptx3
gancyclovir
alone
Prior art date
Application number
HRP20120676TT
Other languages
English (en)
Croatian (hr)
Inventor
Romani Luigina
Bistoni Francesco
Garaci Enrico
Original Assignee
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. filed Critical Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Publication of HRP20120676T1 publication Critical patent/HRP20120676T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20120676TT 2006-05-02 2007-04-12 Uporaba tiomiozina 1, samog ili u kombinaciji s ptx3 ili ganciklovirom, za liječenje citomegalovirusne infekcije HRP20120676T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06113401 2006-05-02
PCT/EP2007/053574 WO2007128647A1 (en) 2006-05-02 2007-04-12 USE OF THYMOSIN α1, ALONE OR IN COMBINATION WITH PTX3 OR GANCICLOVIR, FOR THE TREATMENT OF CYTOMEGALOVIRUS INFECTION

Publications (1)

Publication Number Publication Date
HRP20120676T1 true HRP20120676T1 (hr) 2012-09-30

Family

ID=36658736

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20120676TT HRP20120676T1 (hr) 2006-05-02 2007-04-12 Uporaba tiomiozina 1, samog ili u kombinaciji s ptx3 ili ganciklovirom, za liječenje citomegalovirusne infekcije

Country Status (18)

Country Link
US (1) US8337828B2 (enExample)
EP (1) EP2012816B1 (enExample)
JP (1) JP5441685B2 (enExample)
KR (1) KR101380360B1 (enExample)
CN (1) CN101437535B (enExample)
AU (1) AU2007247292B2 (enExample)
BR (1) BRPI0711136A2 (enExample)
CA (1) CA2649063C (enExample)
CY (1) CY1113277T1 (enExample)
DK (1) DK2012816T3 (enExample)
ES (1) ES2389452T3 (enExample)
HR (1) HRP20120676T1 (enExample)
MX (1) MX2008013872A (enExample)
PL (1) PL2012816T3 (enExample)
PT (1) PT2012816E (enExample)
RS (1) RS52377B (enExample)
SI (1) SI2012816T1 (enExample)
WO (1) WO2007128647A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1298487B1 (it) * 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
ITRM20040223A1 (it) * 2004-05-07 2004-08-07 Sigma Tau Ind Farmaceuti Medicamento per il trattamento delle infezioni fungine, in particolare dell'aspergillosi.
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
US8829173B2 (en) * 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
CN102458470B (zh) * 2009-05-08 2016-01-20 赛生制药有限公司 作为疫苗增强剂的α胸腺素肽
EP2675272A4 (en) * 2011-02-09 2015-03-11 Sciclone Pharmaceuticals Inc THYMOSINE ALPHA PEPTIDE FOR THE PREVENTION, TREATMENT AND TREATMENT OF INFECTIONS
JP6419706B2 (ja) 2012-10-25 2018-11-07 トカジェン インコーポレーテッド ミニプロモーターカセットを含むレトロウイルスベクター

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6106868A (en) 1990-08-24 2000-08-22 The Board Of Governors Of Wayne State University Method for the treatment of hepatitis
TW224053B (enExample) * 1991-09-13 1994-05-21 Paul B Chretien
CN1072961C (zh) * 1993-03-05 2001-10-17 施塞克龙药品公司 治疗对干扰素治疗无反应者的丙型肝炎的方法
US6200952B1 (en) * 1993-06-02 2001-03-13 Sciclone Pharmaceuticals, Inc. Combination therapy method for treating chronic hepatitis B
US5632983A (en) * 1994-11-17 1997-05-27 University Of South Florida Method for treating secondary immunodeficiency
WO1998018491A1 (en) * 1996-10-28 1998-05-07 BURGSTINER, Jacqueline, Cook Methods and compositions for dietary supplementation
US5939423A (en) 1997-04-16 1999-08-17 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir
IT1298487B1 (it) * 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
US6288033B1 (en) 1998-09-25 2001-09-11 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis B infection with thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir
IT1317927B1 (it) 2000-11-03 2003-07-15 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie autoimmuni.
IT1317930B1 (it) 2000-11-08 2003-07-15 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione
PT1411971E (pt) 2001-08-03 2006-07-31 Sigma Tau Ind Farmaceuti Utilizacao de pentraxina longa ptx3 para o tratamento de infertilidade feminina
WO2003035111A1 (en) 2001-10-24 2003-05-01 Sciclone Pharmaceuticals, Inc. Antiretroviral compositions comprising thymosin alpha peptides and protease inhibitors
US20070036744A1 (en) * 2003-04-23 2007-02-15 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides
ITRM20030596A1 (it) 2003-12-23 2005-06-24 Sigma Tau Ind Farmaceuti Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3.
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases

Also Published As

Publication number Publication date
DK2012816T3 (da) 2012-09-03
KR101380360B1 (ko) 2014-04-09
BRPI0711136A2 (pt) 2011-08-30
US8337828B2 (en) 2012-12-25
CA2649063C (en) 2014-11-25
WO2007128647A1 (en) 2007-11-15
MX2008013872A (es) 2008-11-14
SI2012816T1 (sl) 2012-09-28
AU2007247292A1 (en) 2007-11-15
US20090275508A1 (en) 2009-11-05
CN101437535A (zh) 2009-05-20
ES2389452T3 (es) 2012-10-26
EP2012816A1 (en) 2009-01-14
JP2009535373A (ja) 2009-10-01
RS52377B (sr) 2012-12-31
HK1128622A1 (en) 2009-11-06
PT2012816E (pt) 2012-08-17
PL2012816T3 (pl) 2012-11-30
KR20090007621A (ko) 2009-01-19
CN101437535B (zh) 2013-01-30
CY1113277T1 (el) 2016-04-13
AU2007247292B2 (en) 2012-04-05
CA2649063A1 (en) 2007-11-15
JP5441685B2 (ja) 2014-03-12
EP2012816B1 (en) 2012-06-27

Similar Documents

Publication Publication Date Title
HRP20120676T1 (hr) Uporaba tiomiozina 1, samog ili u kombinaciji s ptx3 ili ganciklovirom, za liječenje citomegalovirusne infekcije
Witte et al. Interleukin-22: a cytokine produced by T, NK and NKT cell subsets, with importance in the innate immune defense and tissue protection
PH12015500773B1 (en) Methods and compositions for live attenuated viruses
CL2011000742A1 (es) Virus herpes bovino 1 (bhv-1) que posee modificaciones de ul49.5 y al menos un gen adicional que codifica una proteina que puede suprimir el sistema inmune de un huesped infectado, que se selecciona a partir de ul41,us4, y su combinacion.
CL2013001471A1 (es) Composicion que comprende al menos una n-acetil-lactosamina, al menos un oligosacarido sialilado y al menos un oligosacarido fucosilado y un hidrolizado que comprende proteinas parcialmente y/o completamente hidrolizadas; y su uso para la prevencion y/o tratamiento de las condiciones de la piel y enfermedades de la piel.
HRP20241701T1 (hr) Modificirani nukleozidi, nukleotidi i nukleinske kiseline i njihova uporaba
ATE503769T1 (de) Antikörper gegen das humane cytomegalie-virus (hcmv)
MX341842B (es) Virus de la influenza capaces de infectar canidos y usos de los mismos.
CY1112848T1 (el) Αναστολεις του ιου της ηπατιτιδας c
WO2009025743A3 (en) Use of trail compositions as antiviral agents
EP1948229A4 (en) COMBINATION VACCINE WITH A STEAMED BOVINE VIRUS DIARRHEA VIRUS
WO2008045120A3 (en) Transgenic mouse lines expressing human ace2 and uses thereof
HRP20110713T1 (hr) Postupci liječenja kroničnog virusnog hepatitisa c uz upotrebu ro 113-0830
IN2012DN03178A (enExample)
ATE547118T1 (de) Rekombinanter koi-herpesvirus (khv) oder cyprinid-herpesvirus 3 (cyhv-3) und impfstoff zur prävention einer von khv/cyhv-3 bei cyprinus carpio carpio oder cyprinus carpio koi verursachten erkrankung
MX2010001849A (es) Depsipeptidos ciclicos.
BRPI0922701A8 (pt) Método para intensificar atividade viral mediada por interferon em um animal de companhia
PH12013501373B1 (en) Bovine viral diarrhea virus type 1b vaccine compositions and methods
EP2495326A3 (en) Materials and methods for respiratory disease control in canines
ATE549031T1 (de) Impfstoffzusammensetzung zur prävention von cmv- infektionen
Ma et al. Reverse genetic systems: Rational design of coronavirus live attenuated vaccines with immune sequelae
AR094810A1 (es) Parvovirus porcino 5b, métodos de uso y vacuna
BRPI0600195A (pt) composição aquosa
EA201070806A1 (ru) Состав медленного высвобождения на основе ассоциации гликогена и альгината
ES2544153A1 (es) Uso de un hidrolizado de caseína como agente antiviral